Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Heron Therapeutics Inc (HRTX) Price & Performance

MicroSectors FANG and Innovation 3X Leveraged ETNTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

MicroSectors FANG and Innovation 3X Leveraged ETN vs Heron Therapeutics Inc — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.21, while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

FNGUHRTX
Sector
Leveraged / InverseHealth
52-Week High
$36.15$1.49
52-Week Low
$13.73$0.32
Market Cap
$61.47M
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU, a 3X leveraged ETN tracking the FANG+ Index, trades at $32.53, down 3.47% on the day. Technical indicators show a bullish trend with moving averages supporting upside, though RSI levels suggest overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the product's leveraged risk.

The outlook for FNGU hinges on continued strength in mega-cap tech stocks, but risks are elevated due to leverage decay and market volatility. Investors face potential for amplified gains or losses, with sentiment cautious amid recent sharp declines. Careful risk management is essential given the ETN's structure.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MicroSectors FANG and Innovation 3X Leveraged ETN

FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.

Read more on FNGU

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX